mProX™ Human FLT1 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1144	Magic™ Human FLT1(VEGFR1) in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

FLT1

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

CNS Research

Related Diseases

Pre-Eclampsia and Eclampsia. Among its related pathways are Apoptotic Pathways in Synovial Fibroblasts and GPCR Pathway

Gene ID

2321

UniProt ID

P17948

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

Fms-related tyrosine kinase 1 (FLT1) is a gene that encodes a protein that is a receptor tyrosine kinase in the vascular endothelial growth factor receptor (VEGF) family. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer. FLT1 is altered in 3.07% of all cancers with lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, melanoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations. The customized FLT1 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Sandra

High quality and reliable FLT1 cell line. Sep 04 2021

chat Verified Customer

chat Karen

This FLT1 cell line saved us time and resources. Plus, the technical support from the company was outstanding-prompt and helpful. Jan 12 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 5-aza-2'-deoxycytidine (5azadC) enhances FLT1 expression and induces sFLT1 secretion in choriocarcinoma cells.

The mRNA expression levels of three FLT1 splice variants in the three choriocarcinoma cell lines were examined. The cells were cultured for five days in the presence of either 10 μM 5azadC or 0.1% DMSO (vehicle control). Culture media were replaced every day, and on the fifth day, the conditioned media were collected for ELISA and Western blotting.

Ref: Sasagawa, Tadashi, et al. "Production of an anti-angiogenic factor sFLT1 is suppressed via promoter hypermethylation of FLT1 gene in choriocarcinoma cells." BMC cancer 20.1 (2020): 1-13.

Pubmed: 32041578

DOI: 10.1186/s12885-020-6598-9

Research Highlights

An intriguing development in the biology of preeclampsia is the fetal preeclampsia genome-wide association research, which indicates that a basic molecular abnormality in preeclampsia is dysregulation at the Fms-like tyrosine kinase 1 locus in the fetal genome (probably in the placenta).
Gray, Kathryn J., Richa Saxena, and S. Ananth Karumanchi. "Genetic predisposition to preeclampsia is conferred by fetal DNA variants near FLT1, a gene involved in the regulation of angiogenesis." American journal of obstetrics and gynecology 218.2 (2018): 211-218.
Pubmed: 29138037 DOI: 10.1016/j.ajog.2017.11.562

Because CSF1 is epistatic to FLT1, there is a connection between inflammation in breast tumor metastases and FLT1. Significantly, even after initial seeding, FLT1 inhibition lowers tumor metastatic efficiency, indicating that these pathways may serve as therapeutic targets in metastatic illness.
Qian, Bin-Zhi, et al. "FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis." Journal of Experimental Medicine 212.9 (2015): 1433-1448.
Pubmed: 26261265 DOI: 10.1084/jem.20141555